NCT Number: NCT02194127
Efficacy and Tolerability of a Bilberry Extract in Volunteers With Impaired Twilight and Night Vision
Study to determine the efficacy of Anthocyan to improve impaired twilight and night vision and to test its tolerability and safety.
Looking for future studies?
Notify MeKey information
Conditions
Age range
50 year–70 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy subjects (volunteers) with age-related impaired twilight and night
- Age 50 to 70, men or women
- Written informed consent
- Full visual acuity (vision ≥ 0.7) according to DIN Standard condition
- Refraction ≤ +/-6.0 in the highest main step
- Age-related findings in the ophthalmologic examination (anterior chamber and eye ground)
- Normal intraocular pressure (10-20 mmHg)
Exclusion criteria
- Diabetes mellitus
- Epilepsy
- Abnormal visual acuity or eye ground (e.g. clouding of the lens)
- Age related vision problems
- Glaucoma and macular degeneration
- Disease of the retina
- Consumption of anthocyan preparations during the past six months
- Opthalmologic pathology: cataract, visus < 0.7, retinal pathology, maculopathy, intraocular pressure (> 21 mmHg), known acute or chronic eye disease, use of hard contact lenses, eye surgery performed within the last 12 months
- Any serious disorder that might interfere with his/her participation in this study and the evaluation of the efficacy or safety of the test drug: e.g. diabetes mellitus, anamnestic indications of diabetic microangiopathy or polyneuropathy, renal insufficiency, hepatic or metabolic dysfunction, cardiovascular disease (hypertension > 160/100 mmHg), psychiatric disorder, myasthenia gravis, delirious state, albino
- Any treatment that might interfere with the evaluation of the test drug, in particular drugs with known influence on eye sight or adaptation (e.g. chloroquine, digitalis, ethambutol, chlorpromazine or phenothiazine derivatives such as thioridazine, periciazine, perphenazine)
- Known hypersensitivity to any of the ingredients of the study drug
- Drug and alcohol abuse
- Pregnancy, lactation, women of childbearing potential who do not use an established contraceptive
- Participation in another trial within the past 30 days
Treatment and study plan
Placebo
DrugPrimary outcomes
-
Measurement of the maximum velocity of dilatation of the pupil
Time frame: day 29
Secondary outcomes
-
Measurement of the maximum velocity of dilatation of the pupil
Time frame: Days 1 and 8
-
Measurement of the initial pupil diameter
Time frame: days 1, 8 and 29
-
Measurement of the latency time
Time frame: Days 1, 8 and 29
-
Measurement of the absolute and relative constriction amplitude
Time frame: Days 1, 8 and 29
-
Measurement of maximum velocity of contraction
Time frame: Days 1, 8 and 29
-
Measurement of velocity of contraction 2
Time frame: Days 1, 8 and 29
-
Measurement of initial minimal contrast level
Time frame: Days 1, 8 and 29
Determined with Gecko Contrast card
-
Time to regain contrast vision at one level above the initial minimal contrast
Time frame: days 1, 8 and 29
Determined with Gecko Contrast card
-
Measurement of contrast threshold level at illumination 0.1 cd/m2 with glare
Time frame: Days 1, 8 and 29
determined with Mesoptometer II
-
Measurement of contrast threshold level at illumination 0.032 cd/m2 without glare
Time frame: Days 1, 8 and 29
determined with Mesoptometer II
-
Recovery time after dazzling
Time frame: Days 1, 8 and 29
-
Change of potential (µVolt) in retina due to photo activation
Time frame: Baseline, days 1, 8 and 29
Measured with Standard Electroretinography (ERG)
-
Assessment of subjective efficacy based on a visual analogue scale (VAS) rating questionnaire
Time frame: Pre-dose and days 1, 8 and 29
-
Assessment of clinical global impression on a 5-point rating scale
Time frame: Day 29
-
Number of patients with adverse events
Time frame: up to day 29
-
Number of patients with significant changes in laboratory parameters
Time frame: Baseline and day 29
Sponsors and collaborators
Lead sponsor
Boehringer Ingelheim
Industry
Registry information
Official study title
Efficacy and Tolerability of a Treatment Over 28 Days With a Bilberry Extract Standardised to a Content of 25% Anthocyanidines in Volunteers With Impaired Twilight and Night Vision
Important dates
- Study start
- 1998
- Primary completion
- 1999
- First posted
- Jul 18, 2014
- Registry last updated
- Jul 24, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Tumor-Derived FGF19
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsAI Chatbot for HPV Vaccine Literacy Among Caregivers in Japan
NCT06702423
Healthy
London, United Kingdom
View Trial DetailsValidation of the Masimo Irregular Heartbeat Detection Algorithm in Participants Without Cardiovascular Disease
NCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNormative Value for Navicular Drop Test in Older Adults
NCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details